Figure 3.

Progression-free probability across post-diagnosis months for neuroblastoma RAS viral (v-RAS) oncogene homolog (Nras). Progression-free probability across post-diagnosis months for individuals with Low (25th percentile) and High (75th percentile) expression level of neuroblastoma RAS viral (v-RAS) oncogene homolog (Nras). With a high hazard estimate (HR = 3.93), the progression-free probability falls faster in individuals with high expression levels of Nras.

SerĂ£o et al. BMC Medical Genomics 2011 4:49   doi:10.1186/1755-8794-4-49
Download authors' original image